Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Non-Current Deffered Revenue: 2014-2018

Historic Non-Current Deffered Revenue for ImmunityBio (IBRX) over the last 4 years, with Dec 2018 value amounting to $2.7 million.

  • ImmunityBio's Non-Current Deffered Revenue fell 17.62% to $2.7 million in Q4 2018 from the same period last year, while for Dec 2018 it was $2.7 million, marking a year-over-year decrease of 17.62%. This contributed to the annual value of $2.7 million for FY2018, which is 17.62% down from last year.
  • According to the latest figures from Q4 2018, ImmunityBio's Non-Current Deffered Revenue is $2.7 million, which was down 5.45% from $2.9 million recorded in Q3 2018.
  • Over the past 5 years, ImmunityBio's Non-Current Deffered Revenue peaked at $3.6 million during Q2 2017, and registered a low of $3,000 during Q2 2015.
  • In the last 3 years, ImmunityBio's Non-Current Deffered Revenue had a median value of $2.8 million in 2018 and averaged $2.7 million.
  • Per our database at Business Quant, ImmunityBio's Non-Current Deffered Revenue spiked by 64,033.33% in 2016 and then decreased by 17.62% in 2018.
  • Quarterly analysis of 5 years shows ImmunityBio's Non-Current Deffered Revenue stood at $521,000 in 2014, then spiked by 62.19% to $845,000 in 2015, then soared by 187.10% to $2.4 million in 2016, then spiked by 37.06% to $3.3 million in 2017, then declined by 17.62% to $2.7 million in 2018.
  • Its Non-Current Deffered Revenue stands at $2.7 million for Q4 2018, versus $2.9 million for Q3 2018 and $3.0 million for Q2 2018.